Spectral Medical Inc
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Spectral Medical Inc. (EDT.TO) develops and commercializes innovative technologies for the treatment and diagnosis of septic shock and other life-threatening conditions. The company offers its proprietary Polymyxin B Hemoperfusion technology under the Toraymyxin brand, a therapeutic blood purification device that removes endotoxin from the bloodstream of patients suffering from endotoxemia and septic shock; it also provides diagnostic products including the Endotoxin Activity Assay (EAA), a rapid bedside test measuring endotoxin levels in whole blood, and the recently launched T3 EAA assay for enhanced detection accuracy. Spectral Medical operates primarily in the healthcare and medical technology sectors, targeting critical care units, hospitals, and clinicians managing sepsis patients across North America, Europe, and select Asia-Pacific markets; the company was founded in 1991 and is headquartered in Toronto, Canada. In recent developments, Spectral Medical has advanced its clinical pipeline with positive interim data from the Tigris trial in 2025, evaluating PMX in high-risk cardiac surgery patients, building momentum toward full enrollment and potential regulatory submissions. The company strengthened its strategic positioning through a renewed distribution agreement with Toray Medical Co., Ltd. in early 2025, expanding access to Toraymyxin in key international markets; additionally, it secured CAD 10 million in financing via an at-the-market equity offering in late 2024 to support ongoing R&D and commercialization efforts. Spectral Medical continues to focus on sepsis therapeutics without subsidiaries or parent affiliations, emphasizing FDA and Health Canada approvals for its core technologies.
Company News
Spectral Medical Announces U.S. FDA Filing of PMA Application for PMX
Spectral Medical Inc. Announces Results of Annual and Special Meeting of Shareholders
Spectral Medical Inc. (EDT:CA) Shareholder/Analyst Call Transcript
Spectral Medical and Vantive Announce Topline 12 Month Follow-Up Results From Spectral's Tigris Trial
Spectral Medical Announces PMA Submission to U.S. FDA for PMX
Spectral Medical Announces First Quarter 2026 Financial Results and Provides Corporate Update
Spectral Medical Inc. Announces Participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Spectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate Update
Spectral Medical and Vantive Announce Publication of Complete Results from Spectral's Tigris Trial in the Lancet Respiratory Medicine
Spectral Medical Provides Update on PMA Submission Timing for PMX-20R
Spectral Medical Inc. (EDT:CA) Discusses Year-End Update: FDA Filing Timeline, Tigris Trial Results, and Commercialization Readiness Transcript
Reviewing SiBone (NASDAQ:SIBN) & Spectral Diagnostics (OTCMKTS:EDTXF)
Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF
Spectral Medical Announces Publication of EDEN Observational Study
Spectral Medical Receives US$3 Million From Vantive
Spectral Medical and Vantive Announce Topline Results from Spectral's Tigris Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic Shock
Spectral Medical Announces Second Quarter and Provides Corporate Update
Spectral Medical Inc. Announces Filing of Base Shelf Prospectus
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders
Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference